Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Di Sun

Showing results (1081-1090 of 1,085) with videos related to

Pageof 109
Sort By:
You have reached the last page of results.This site can display upto 1,085 results.
The Journal of Experimental Medicine|May 5, 2021
Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patientsCarole Le Coz, David N Nguyen, Chun Su, et al.
Blood|January 24, 2025
One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying themAinsley V C Knox, Lauren Y Cominsky, Di Sun, et al.
Medcomm|July 24, 2023
Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: A multicohort studyLe Qu, Hui Chen, Qi Chen, et al.
Chinese Medical Journal|November 19, 2013
Efficacy and safety of Changfu peritoneal dialysis solution: a multi-center prospective randomized controlled trialJian-Hui Zhou, Zhao-Hui Ni, Chang-Lin Mei, et al.
European Urology Oncology|July 19, 2023
Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant TherapyZhenjie Wu, Hui Chen, Qi Chen, et al.
Pageof 109

Showing results (1081-1090 of 1,085) with videos related to

Sort By:
Pageof 109
You have reached the last page of results.This site can display upto 1,085 results.
The Journal of Experimental Medicine|May 5, 2021
Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patientsCarole Le Coz, David N Nguyen, Chun Su, et al.
Blood|January 24, 2025
One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying themAinsley V C Knox, Lauren Y Cominsky, Di Sun, et al.
Medcomm|July 24, 2023
Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: A multicohort studyLe Qu, Hui Chen, Qi Chen, et al.
Chinese Medical Journal|November 19, 2013
Efficacy and safety of Changfu peritoneal dialysis solution: a multi-center prospective randomized controlled trialJian-Hui Zhou, Zhao-Hui Ni, Chang-Lin Mei, et al.
European Urology Oncology|July 19, 2023
Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant TherapyZhenjie Wu, Hui Chen, Qi Chen, et al.
Pageof 109